- April 13, 2021
- Posted by: OptimizeIAS Team
- Category: DPN Topics
Subject: Science & tech
Context: The curious case of VIPIT: Studies needed to identify susceptibility markers, diagnostic tests, treatments.
- The United Kingdom, European Union, and Scandinavian countries have reported that the AstraZeneca COVID-19 vaccine appears to be associated with rare cases of serious blood clots, including blood clots in the brain.
- These blood clots have two important features: they occur 4 to 20 days after vaccination, and they are associated with low platelets (tiny blood cells that help form blood clots to stop bleeding).
- Doctors are calling this “vaccine-induced prothrombotic immune thrombocytopenia” (VIPIT).
- VIPIT seems to be rare, occurring in anywhere from 1 in every 125,000 to 1 in 1 million people.
- There have been no confirmed cases of VIPIT with any other COVID-19 vaccine.